The first module of Myriad Genetics' premarket approval application for its BRACAnalysis test has been forwarded to the FDA. The company is seeking to have the assay approved for use as a companion diagnostic to identify ovarian cancer patients who would most likely benefit from AstraZeneca's experimental drug olaparib by identifying those with BRCA mutations.

Related Summaries